We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Biomarkers to Predict Aggressive Prostate Cancer

Video   Mar 31, 2015

 


About the Speaker
Claire gained her PhD in 2002 and since then has worked in the field of cancer research. Claire has previously held a post at the prestigious MRC Cancer Cell Unit in Cambridge, UK before returning to Swansea University. Claire is now based at the Institute of Life Science where one of her research aims is concerned with identifying prognostic biomarkers for clinical management of prostate cancer and pancreatic cancer patients. Claire is also a Senior Lecturer in Genetics and teaches on the Genetics and Medical Genetics BSc degree schemes and Graduate Entry Medicine in the College of Medicine.Abstract
Prostate cancer (CaP) is the most common cancer in men in the UK. Every year nearly 40,000 cases of CaP are diagnosed and it accounts for approximately 12% of all male deaths from cancer in the UK. Early diagnosis of organ-confined CaP is essential since radical prostatectomy or radiotherapy offers the only chance of complete cure and treatment of advanced disease is palliative and in-effective (in the long term). In addition, early organ-confined CaP is not always life threatening and can follow and indolent course which does not require treatment. It is generally accepted that currently available methods used for diagnosis and staging of CaP (prostate specific antigen levels, Gleason score and clinical and pathological grade) lack the sensitivity to distinguish between patients with indolent, organ-confined CaP, those requiring radical treatment and those at risk of relapse after radical treatment. Clearly there is a need to identify molecular markers of CaP progression, invasion and metastasis to predict diagnosis and guide therapy. Due to the heterogeneous nature of cancer, analysis of single molecules provides limited information and it is impossible to diagnose cancer or predict disease progression using a single biomarker. Therefore there is a need to a identify a panel of biomarkers that may distinguish indolent cancer from aggressive metastatic disease when used collectively

 
 
 
 

Recommended Videos

What is Leukemia?

Video

Stem cells found in the bone marrow are crucial for our health because they are needed to become new blood cells that sustain and protect our bodies. But when the transformation goes wrong, harmful mutations can cause the cells to start replicating without control -- a type of cancer known as leukemia.

WATCH NOW

Genetic Causes of Myeloma

Video

Myeloma occurs as a result of changes in the genetic material within plasma cells. This animation explains what happens at the genetic level which causes myeloma to develop.

WATCH NOW

Cancer Cell Biology: Mutated KRAS & Reciprocal Signaling

Video

Across a wide variety of cancer types, a protein called KRAS can get hyperactivated and transmit an overload of unwanted growth signals to the cells, causing them to divide and form a tumor.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE